CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
View Patent ↗The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.
1. A method for determining the prognosis of and aggressiveness of disease in a subject with B cell chronic lymphocytic leukemia (“B-CLL”), the method comprising:
analyzing Ig V H and Ig V L genes expressed in B-CLL cells from a blood sample from the subject to determine whether the B-CLL cells contain unmutated Ig V H and Ig V L genes,
wherein the presence of unmutated Ig V H and Ig V L genes in the B-CLL cells is determined by assessing whether the DNA sequence of the Ig V H and Ig V L genes of the B-CLL cells of the sample is <2% different from a control germline DNA sequence of Ig V H and Ig V L genes,
wherein the presence of unmutated Ig V H and Ig V L genes indicates an aggressive disease course and poor prognosis versus an indolent disease course.
2. The method of claim 1 , wherein the Ig V H and Ig V L genes are analyzed by sequencing cDNA of the Ig V H and Ig V L genes made from the B-CLL cells.
3. The method of claim 1 , wherein the control germline DNA sequence is selected from germline DNA sequences of multiple B-CLL patients, and wherein the control germline DNA sequence so selected has the most similar germline DNA sequence in both expressed Ig V H and Ig V L genes as the Ig V H and Ig V L genes from the subject.
4. A method for evaluating whether a subject with B cell chronic lymphocytic leukemia (“B-CLL”) should undergo an aggressive course of treatment, the method comprising:
analyzing Ig V H and Ig V L genes expressed in B-CLL cells from a blood sample from the subject to determine whether the B-CLL cells contain unmutated Ig V H and Ig V L genes,
wherein the presence of unmutated Ig V H and Ig V L genes in the B-CLL cells is determined by assessing whether the DNA sequence of the Ig V H and Ig V L genes of the B-CLL cells of the sample is <2% different from a control germline DNA sequence of Ig V H and Ig V L genes,
wherein the presence of unmutated Ig V H and Ig V L genes indicates the subject should undergo an aggressive course of treatment.
5. The method of claim 4 , wherein the Ig V H and Ig V L genes are analyzed by sequencing cDNA of the Ig V H and Ig V L genes made from the B-CLL cells.
6. The method of claim 4 , wherein the control germline DNA sequence is selected from germline DNA sequences of multiple B-CLL patients, and wherein the control germline DNA sequence so selected has the most similar germline DNA sequence in both expressed Ig V H and Ig V L genes as the Ig V H and Ig V L genes from the subject.